ARTHEx Biotech Announces Closing of €42 M Series B Financing

Complement Therapeutics Secures €72 Million in Series A Financing

Alex Therapeutics extends financing round to €4.75M with leading life science VC

Alex Therapeutics and Vicore Pharma today announce the first study subject enrolled in the pivotal study COMPANION evaluating Almee™

Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas

Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study

Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

Cardior Announces First Patient Dosed in Phase 2 Study

Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis

Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension

Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro in patients with acute pulmonary hypertension

Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors

Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation by the FDA

Alex Therapeutics raises €3.5M in oversubscribed financing round

TargED Biopharmaceuticals raises EUR 39 Million in Series A financing

Ribbon Biolabs raises EUR 18 million in its Series A financing

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Hadean Ventures Announces the 1st Closing of EUR 90m for its Second Fund

Cardior raises €64 M Series B to advance clinical pipeline of RNA therapeutics to treat Cardiac Disease

Attgeno appoints Björn Westberg as CFO

SAGA Diagnostics raises €10.5 million

Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round

Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

Join Hadean Ventures!

Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin®

Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies

Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial

Pipeline Therapeutics Completes $80 Million Series C Financing

Ekspertenes biotekfavoritter i urolige tider, e24.no

Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS- 248 in patients with systemic sclerosis

Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage

Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients

Helsestartups får stryk på mangfold, e24.no

Galecto Publishes GB0139 Phase 2a (IPF) Results in European Respiratory Journal

Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan

Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021

Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial

Galecto Announces Pricing of Initial Public Offering

Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli®

Abliva doses the first patient in its KL1333 Phase Ia/b clinical study

Hadean Ventures invest in Galecto`s $64 million round equity financing

Ingrid Teigland Akay included in Business Insider’s list of 100 People Transforming Business in Europe.

Abliva intends to start a pivotal KL1333 study second half 2021

Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial

Pewin Member Highlight 2020: Ingrid Teigland Akay

CardioMech AS Announces $18.5M Series A for its Transcatheter Mitral Valve Repair Technology

Abliva receives positive FDA feedback on its KL1333 development plan

Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss

Gesynta raises SEK 190 million in round led by Hadean Ventures to accelerate development of first-in-class mPGES-1 inhibitor GS-248 for systemic sclerosis

€1.9M EU funding takes Nelli® available for all epilepsy patients

Abliva completes the directed issue of MSEK 20 to Hadean Ventures

Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial

Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial

MSD to Acquire Themis

NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures

Varsler massive coronakjøp, Finansavisen

Neuro Event Labs Oy closes EUR 3.9m Series A investment round from Hadean Ventures, SHS Gesellschaft für Beteiligungsmanagement and Maki.vc

Themis and Institut Pasteur Join Coronavirus Vaccine Hunt

Pipeline Therapeutics Completes $30 Million Series B Financing

Hadean Ventures receives Rising Star Award at the 10th edition of the Private Equity Exchange & Awards 2019 in Paris

Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round

Hadean Ventures leads 40 million SEK (€3.7 million) investment round into SAGA to advance ultrasensitive cancer liquid biopsies

Hadean Ventures’ Ingrid Teigland Akay receives Investor of the Year award at the SHE conference

Level 20 selects Ingrid Teigland Akay as one of nine Inspiring Women in European Private Equity

Hadean Ventures is pleased to announce the appointment of Roger Franklin PhD as Partner to be based in Hadean’s Stockholm office at the Karolinska Institute Science Park.

Hadean Ventures, SINTEF Venture V and Investinor invest in Nisonic AS to develop advanced ultrasound technology for neurological conditions.

Investorview: Plugging knowledge gaps to accelerate life science start-up development

Hadean Ventures today announces an investment in AttgeNO AB, a Swedish pharmaceutical company developing treatments for acute life-threatening conditions.

Hadean Ventures launches new fund to leverage untapped potential of European life science startups